ProQR Therapeutics N.V. (PRQR) Raised to Buy at Zacks Investment Research
Zacks Investment Research upgraded shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) from a hold rating to a buy rating in a report published on Tuesday morning. Zacks Investment Research currently has $5.25 price objective on the biopharmaceutical company’s stock.
According to Zacks, “ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company’s lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. “
Separately, HC Wainwright reissued a buy rating and set a $40.00 price target on shares of ProQR Therapeutics N.V. in a report on Tuesday, June 20th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus price target of $14.15.
Shares of ProQR Therapeutics N.V. (PRQR) opened at 4.50 on Tuesday. ProQR Therapeutics N.V. has a one year low of $3.65 and a one year high of $8.70. The firm’s market cap is $108.47 million. The firm’s 50-day moving average price is $5.03 and its 200 day moving average price is $4.83.
A number of hedge funds have recently added to or reduced their stakes in PRQR. Hikari Power Ltd bought a new stake in ProQR Therapeutics N.V. during the first quarter valued at about $121,000. Redmile Group LLC raised its stake in ProQR Therapeutics N.V. by 2.8% in the second quarter. Redmile Group LLC now owns 1,596,275 shares of the biopharmaceutical company’s stock valued at $8,301,000 after buying an additional 43,050 shares in the last quarter. Artal Group S.A. raised its stake in ProQR Therapeutics N.V. by 25.0% in the second quarter. Artal Group S.A. now owns 500,000 shares of the biopharmaceutical company’s stock valued at $2,600,000 after buying an additional 100,000 shares in the last quarter. Sphera Funds Management LTD. raised its stake in ProQR Therapeutics N.V. by 65.0% in the first quarter. Sphera Funds Management LTD. now owns 330,000 shares of the biopharmaceutical company’s stock valued at $1,650,000 after buying an additional 130,000 shares in the last quarter. Finally, Janus Henderson Group PLC bought a new stake in ProQR Therapeutics N.V. during the second quarter valued at about $2,028,000. 35.70% of the stock is owned by institutional investors and hedge funds.
ProQR Therapeutics N.V. Company Profile
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for ProQR Therapeutics N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics N.V. and related stocks with our FREE daily email newsletter.